Skip to main content

Table 4 Hazard ratios of time to death (any cause), without PTH, Ca and P

From: Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study

  HR 95% CI p-value
Age (per 10 year increase) 1.33 0.99 1.80 0.06
Gender (male vs female) 1.22 0.63 2.36 0.55
History of hypertension (yes vs no) 0.32 0.10 0.98 0.05
History of dyslipidemia (yes vs no) 0.94 0.42 2.09 0.88
Heart disease (yes vs no) 1.62 0.73 3.58 0.24
Neoplasias (yes vs no) 2.15 0.93 5.00 0.07
Liver disease (yes vs no) 2.04 0.77 5.41 0.15
Vascular disease (yes vs no) 4.60 2.04 10.38 0.00
Treatment of diabetes (yes vs no) 1.61 0.71 3.61 0.25
Hemoglobin (per 1 g/dl increase) 0.64 0.49 0.84 0.00
Albumin (per 1 g/dl increase) 1.12 0.87 1.45 0.38
VDRA (no vs yes) 2.69 1.38 5.22 0.00
Ca-based PiB (no vs yes) 1.11 0.47 2.67 0.81
NoCa-based PiB (no vs yes) 0.58 0.27 1.22 0.15
  1. Data presented as hazard ratios (HR) and upper and lower 95% confidence intervals (CI).
  2. PTH = parathyroid hormone; P = phosphorous, Ca = calcium; VDRA = vitamin D receptor activator; Ca-based PiB = calcium containing phosphate binders; noCa-based PiB = non calcium containing phosphate binders. All variables (but age and gender) were included as time dependent covariates. Statistically significant p-values are highlighted in bold.